Your search for major depressive disorder returned 75 results

Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.

Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.

For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.

Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.

Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.

An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.

AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.

More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.

The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.

The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.

American College of Physicians recommends monotherapy with cognitive therapy or second-generation antidepressant for patients in acute phase of moderate-to-severe depression

Researchers compared grey matter volume patterns in adult patients with attention-deficit/hyperactivity disorder and bipolar disorder.

Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.

However, no corresponding increase seen in mental health treatment

Adults with major depressive disorder and a history of childhood trauma can still benefit from recommended depression treatments.

A cross-sectional family study sought to determine if parents’ transmission of anxiety is sex specific.

Inpatients with persistent depressive disorder were recruited at a German University Hospital for a 10-week inpatient treatment with the Cognitive Behavioral Analysis System of Psychotherapy.

For this study, patients with generalized anxiety disorder were recruited from the Nanfang Hospital in China between 2018 and 2020.

Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.

Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.

Investigators assessed the safety and efficacy of lumateperone for the treatment of bipolar I and II disorders in patients experiencing major depressive episodes.

The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial.

For Chinese adults with normal kidney function, higher depressive symptoms are associated with an increased risk for rapid kidney function decline.

Researchers compared how patients experiencing a major depressive episode and control participants perceived contrast patterns.

The percentage of adults with mental health issues increased, as did the percentage reporting that they needed but did not receive help.

Researchers from Dalhousie University in Canada searched publication databases through September of 2020 for articles on ADHD, attention deficit disorder, bipolar disorder, and affective psychosis.

Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.

The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.

Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.

Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.